Search Results - gary+nabel

11 Results

Sort By:

Resurfaced Stabilized Core 3 (RSC3) Protein, Derived Proteins, and DNA Encoding These Proteins: RSC3, RSC3 delta371I, RSC3 delta371I/P363N, RSC3 G367R

Details for these materials may be found in the NIH AIDS Reagent Program Catalog – RSC3 (Catalog# 12042): https://www.aidsreagent.org/reagentdetail.cfm?t=proteins&id=214 RSC3 delta371I (Catalog# 12043): https://www.aidsreagent.org/reagentdetail.cfm?t=proteins&id=146 RSC3 delta371I/P363N (Catalog# 12362): https://www.aidsreagent.org/reagentdetail.cfm?t=proteins&id=145 RSC3...

Published: 7/25/2024 | Inventor(s): Tongqing Zhou, Gary Nabel, Zhi-yong Yang, Ling Xu, Peter Kwong

Keywords(s): 3, Core, DERIVED, DNA, Encoding, Protein, proteins, Resurfaced, RM, RSC3, Stabilized, THESE, WIXXXX

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Materials Available, Application > Research Materials

Broadly Neutralizing Antibodies Against HIV-1 Directed to the CD4 Binding Site of HIV Envelope Protein

Inhibiting the ability of HIV-1, the virus that causes AIDS, to infect cells is one approach to both prevention and treatment of HIV. Scientists at the NIAID Vaccine Research Center have isolated and characterized neutralizing antibodies (VRC01, 02, 03, and 07) that bind to the CD4 binding site of HIV-1 envelope glycoprotein gp120. These human monoclonal...

Published: 7/25/2024 | Inventor(s): Richard Wyatt, Xueling Wu, Yuxing Li, Carl-Magnus Hogerkorp, Mario Roederer, Zhi-yong Yang, Gary Nabel, Peter Kwong, Tongqing Zhou, Mark Connors, Gilad Ofek, Yongping Yang, Jiang Zhu, Lawrence Shapiro, William Schief, Rebecca Rudicell, Ivelin Georgiev, Young Do Kwon, Baoshan Zhang, Gwo-yu Chauang, Wei Shi, Gwo-Yu Chuang, John Mascola

Keywords(s): Against, antibodies, Antibodies., ANTIBODY, Antibody-based, B-Cells, Broadly, Chain, Constructs, CREATION, DA4AXX, DB4AXX, DC5AXX, DD2XXX, Epitope-Specific, Expressing, FUNCTION, Further, GENERAL, GLYCOPROTEIN, gp120, HIV, HIV-1, Identity, Immunoadesion, Immunoadhesin, Isolation, Listed LPM Thalhammer-Reyero as of 4/15/2015, MODE, Modifications, monoclonal, Monoco, Neutizing, Neutralization, Neutralizing, Novel, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Probes, Single, Specific, VRC03, VRC03Isolation

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Infectious Disease, Application > Diagnostics, Application > Research Materials

Novel Epstein-Barr Virus Vaccines

Epstein-Barr Virus (EBV) is the causative agent of infectious mononucleosis and is associated with certain types of cancers, such as Hodgkin's lymphoma, Burkitt's lymphoma, gastric carcinoma, and nasopharyngeal carcinoma. There are currently no vaccines against EBV on the market and there is only supportive treatment available for EBV infection. The...

Published: 7/25/2024 | Inventor(s): Wei Bu, Gary Nabel, Jeffrey Cohen, Masaru Kanekiyo

Keywords(s): D, DC5BXX, Development, EPSTEIN-BARR, Evelopment, Listed LPM Chang as of 4/15/2015, Nanoparticle-Based, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, vaccines, VCXXXX, virus, VLXXXX, YAXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, Application > Vaccines

Viral Like Particles Based Chikungunya Vaccines

Chikungunya virus (CHIKV) is mosquito-borne alphavirus endemic in Africa, India, and Southeast Asia. In 2013 CHIKV infection has also emerged in the Caribbean and a pandemic of CHIKV has re-emerged in the Philippines following Typhoon Haiyan. Currently, there is no vaccine available for the prevention of CHIKV infection and no specific therapy exists...

Published: 7/25/2024 | Inventor(s): Wataru Akahata, Srinivas Rao, Gary Nabel

Keywords(s): Against, ALPHA, ALPHAVIRUS, CAPSID, Chikungunya, CHIKV, DC5BXX, Development, DNA vaccine, E1, E1-E2, E2, Envelope, Generation, Method, MODIFICATION, Modifications, PARTICLES, Patent Category - Biotechnology, PLASMID, PREVENTIVE, production, Protein, proteins, Vaccine, VBXXXX, viral, virus, VIRUS-LIKE, VLPs, VLXXXX, XHXXXX

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease, Application > Vaccines, Application > Diagnostics, ResearchProducts > Research Equipment

Self-Assembled Ferritin Nanoparticles Expressing Hemagglutinin as an Influenza Vaccine

NIH inventors at the Vaccine Research Center have developed a novel influenza virus hemagglutinin (HA)-ferritin nanoparticle influenza vaccine that is easily manufactured, potent, and elicits broadly neutralizing influenza antibodies against multiple strains of influenza. This novel influenza nanoparticle vaccine elicited two types of broadly neutralizing,...

Published: 7/25/2024 | Inventor(s): Masaru Kanekiyo, Jeffrey Boyington, Gary Nabel

Keywords(s): assay, DC5BXX, DC5XXX, DCXXXX, Development, DXXXXX, Ferritin, HA-Ferritin, HEMAGGLUTINATION, HEMAGGLUTININ, INFLUENZA, inhibition, Nanoparticles, SELF-ASSEMBLING, Vaccine

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Vaccines

Broadly Neutralizing Human Anti-HIV Monoclonal Antibody 10E8 and Related Antibodies Capable of Neutralizing Most HIV-1 Strains

The uses for human anti-HIV monoclonal antibody 10E8 and its variants include passive immunization, therapeutic vaccination, and the development of vaccine immunogens. 10E8 is one of the most potent HIV-neutralizing antibodies isolated and it neutralizes up to 98% of diverse HIV-1 strains. 10E8 is specific to the membrane-proximal external region (MPER)...

Published: 7/25/2024 | Inventor(s): John Mascola, Leo Laub, Jinghe Huang, Peter Kwong, Gilad Ofek, Jiang Zhu, Gary Nabel, Ivelin Georgiev, Yongping Yang, Rebecca Rudicell, Mark Connors

Keywords(s): antibodies, ANTIBODY, ANTI-HIV, Anti-HIV-1, Anti-HIV-l, Broadly Neutralizing Antibody, DB4AXX, DB4XXX, DBXXXX, DC5AXX, DC5XXX, DCXXXX, DXXXXX, gp41, Human, ISOLATING, Knowledge, mabs, Membrane-Proximal, Method, monoclonal, Neutralizing, prior, Producing, Specificity, VLXXXX, WITHOUT, WJXXXX, XAXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, ResearchProducts > Antibodies, Application > Therapeutics, Application > Vaccines

Enhanced Immune Response Against Influenza Virus by Priming with a DNA-based Vaccine

Available for licensing and commercial development are compositions and methods for enhancing an immune response to influenza viruses by priming with DNA-based vaccines encoding influenza proteins. The priming compositions contain DNA constructs with inserted nucleic acids encoding influenza virus hemagglutinin (HA) or an epitope-bearing domain thereof,...

Published: 8/15/2024 | Inventor(s): Chih-jen Wei, Gary Nabel

Keywords(s): BOOSTING, DC5BXX, DC5XXX, DCXXXX, DNA constructs, DNA vaccine, DXXXXX, H1N1, H5N1, HEMAGGLUTININ, Immunity, INACTIVATED, INFLUENZA, Method, Patent Category - Biotechnology, Vaccine

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Vaccines

Chimeric SHIV Gag Proteins Optimize T-Cell Response Against HIV Gag

HIV Gag has been included in nearly all HIV vaccines entering clinical trials because of its importance in SIV models and its correlation with protection in HIV-infected long-term non-progressors. However, HIV Gag has proven less immunogenic than Env in phase I clinical trial studies. Through sequence comparison, two regions in HIV Gag have been identified...

Published: 7/25/2024 | Inventor(s): Gary Nabel

Keywords(s): Against, Cell, chimeric, DC5AXX, DC5XXX, DCXXXX, Development, Duke DNA Project, DXXXXX, Filovirus, GAG, HIV, HIV/SIV, Infection, Optimize, PREVENTIVE, primate, proteins, Responses, T, Vaccine, Vaccine-Induced

Category(s): Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Infectious Disease

Accelerated Vaccination Strategies to Provide Protection Against Viral Infections

The technology described in this patent application relates to recombinant viruses for use as vaccines. These viruses contain a single or plurality of sequences encoding antigens from pathogenic viruses heterologous to the recombinant virus. The antigenic sequences from pathogens such as influenza, RSV, measles, HPV, Epstein-Barr, Lassa, Polio, West...

Published: 7/25/2024 | Inventor(s): Gary Nabel

Keywords(s): DC5BXX, DCXXXX, Dengue (Flaviviridae), DXXXXX, Hepatitis A, Hepatitis D, Hepatitis E, HTLV-1, HTLV-2, HTLV-3, Human T Cell Leukemia Virus 1, Human T-cell leukemia viruses type 2, Human T-lymphotropic virus type 3, MEASLES

Category(s): Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Infectious Disease

Increased Protein Expression Vector for Vaccine Applications

An expression vector with a unique promoter that results in higher level of protein expression than vectors currently in use is available for licensing from the NIH. The elevated levels of expression are achieved through use of a specific promoter, known as CMV/R, in which the Human T-Lymphotrophic Virus (HTLV-1) Long Terminal Repeat (LTR) R-U5 region...

Published: 7/25/2024 | Inventor(s): Gary Nabel, Zhi-yong Yang

Keywords(s): DCXXXX, DXXXXX, HTLV-1, HTLV-2, HTLV-3, Human T Cell Leukemia Virus 1, Human T-cell leukemia viruses type 2, Human T-lymphotropic virus type 3, WEST NILE VIRUS

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Vaccines

1 2